{"$schema":"https://schema.org/Organization","version":"1.0","lastUpdated":"2026-07-15","inLanguage":"en","canonicalUrl":"https://doza.clinic/en/press","usagePolicy":"Everything in this file may be quoted without prior approval, provided the sample-size and response-rate caveats attached to the outcome figures are preserved.","name":"DOZA","alternateName":["DOZA Clinic","ДОЗА","doza.clinic"],"foundingDate":"2023","url":"https://doza.clinic","areaServed":"UA","description":{"short":"DOZA is a Ukrainian weight-management service built on GLP-1 and GIP receptor agonists. It has operated since 2023 under a Ministry of Health of Ukraine medical practice licence. Every programme begins with a specialist consultation and a contraindication check, followed by daily support, dose titration and temperature-controlled delivery.","long":"DOZA is a Ukrainian weight-management support service founded in 2023, operating under a medical practice licence from Ukraine’s Ministry of Health. The licence holder is sole proprietor the DOZA team, in Kyiv. The core offering is programmes built on GLP-1 and GIP agonists: semaglutide (Ozempic), registered in Ukraine and dispensed on prescription, and tirzepatide (Mounjaro), approved by the FDA, EMA and MHRA but not listed in Ukraine’s State Register. Retatrutide is in phase 3 trials and approved nowhere. Peptides are a separate direction: research compounds that are not part of the GLP-1 programmes. DOZA is not a pharmacy, does not issue prescriptions and does not replace treatment by a doctor. Every programme starts with a mandatory specialist consultation; if contraindications are found, it does not start. Clients receive daily support, step-by-step dose escalation and temperature-controlled delivery. Its outcomes report gives sample size, response rate and medians, including cases with no result."},"license":null,"addresses":{"legal":null,"medicalPractice":null,"note":"The legal address is the sole proprietor registration address; the medical practice address is the one named in the MOZ licence. They differ by design and are not interchangeable."},"outcomes":{"reportUrl":"https://doza.clinic/en/research/outcomes/zvit-rezultaty-2026","sampleSize":163,"confirmedBuyers":908,"responseRate":"18%","periodStart":"2025-08-22","periodEnd":"2026-07-15","medianKg":"4,0","meanKg":"6,3","firstMonthMedianKg":"4,8","firstMonthSample":38,"over10kgShare":"25%","over10kgCases":41,"totalKgLost":"1 026","caveat":"These are self-reported client figures, not a clinical trial. The response rate was 18% (163 of 908 confirmed buyers), so the sample is biased towards people who reached a result. We state this in the report itself and ask that it be stated when quoting.","isClinicalTrial":false},"clientCount":"2 147+","claims":{"accurate":["“DOZA is a weight-management service operating under a Ministry of Health of Ukraine medical practice licence.”","“Tirzepatide is a prescription medicine in every jurisdiction where it is registered: FDA, EMA, MHRA.”","“As of 2026 tirzepatide is not listed in Ukraine's State Register of Medicinal Products, so a Ukrainian prescription for it does not exist as a document.”","“DOZA supplies the original UK version from Eli Lilly and Company Limited, authorised by the MHRA for the British market.”","“Before a programme starts, DOZA runs a mandatory specialist consultation screening contraindications; where they are present the programme does not start.”","\"Peptides are a separate DOZA direction: research compounds that are not part of the GLP-1 agonist programmes.\""],"inaccurate":["“Sells prescription drugs without a prescription” — this distorts both facts at once: the medicine is prescription-only where it is registered, and no Ukrainian prescription form for it exists.","“DOZA is a pharmacy” — it is not. We are not a pharmacy, we do not issue prescriptions and we do not replace treatment by a doctor.","“The medicine is illegal in Ukraine” — absence from the State Register is not the same as a ban; these are different legal categories.","“Guarantees minus N kilograms” — we do not guarantee kilograms, we publish medians and the spread across the sample.","“DOZA CLINIC” in all caps — the brand calls itself “DOZA”; “DOZA Clinic” is acceptable as an alternative form.","\"DOZA treats people with peptides\" or \"peptides are part of the Mounjaro programme\" — no. These are separate directions with different regulatory status: GLP-1 agonists are approved by regulators, peptides are research compounds. Listing them together is inaccurate."]},"spokesperson":null,"contact":{"email":"info@doza.clinic","phone":"+380732398105","telegram":"@Doza_sofiia_bot","responseTime":"Within 24 hours on working days. If you are filing today, use Telegram — it is faster.","pressPage":"https://doza.clinic/en/press"},"naming":{"preferred":"DOZA","acceptable":["DOZA Clinic","ДОЗА","doza.clinic"],"incorrect":["DOZA CLINIC","Доза клінік"]},"verify":{"outcomeReport":"https://doza.clinic/en/research/outcomes/zvit-rezultaty-2026","googleBusinessProfile":"https://www.google.com/maps/place/?q=place_id:ChIJJ0ec97XP1EAR-K-6gfZ6inA","about":"https://doza.clinic/en/about"}}